COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF CHRONIC SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE NETHERLANDS

Ingelin Kvamme1, Gimon de Graaf1, Susanne Nekeman2, Stijn Gijsbers2, Valérie Wester1,3, Martine Hoogendoorn1

1Institute for Medical Technology assessment, Rotterdam; 2AstraZeneca Netherlands; 3Erasmus School of Health Policy & Management, Rotterdam

Kvamme@imta.eur.nl

This study was financially supported by AstraZeneca

Objective
Heart failure is a leading cause of hospitalization and mortality worldwide, and 242,300 cases were reported in 2018 in the Netherlands alone. Dapagliflozin is a SGLT2 inhibitor registered for treatment for chronic symptomatic heart failure with reduced ejection fraction, among other indications. Aim of this study was to estimate the cost-effectiveness of dapagliflozin in Dutch patients with symptomatic chronic heart failure and a reduced ejection fraction (HFREF) when adding dapagliflozin to standard care (SoC). Dapagliflozin and SoC were compared to SoC alone. The SoC was based on the background treatment as observed in the DAPA-HF trial, which was in accordance with international and national guidelines for SoC for HF treatment [1–2].

Figure 1: Markov model for heart failure

Methods

A Markov model for heart failure with a one-month cycle length (see Figure 1) was developed for assessing dapagliflozin [3]. The analysis was adapted to Dutch guidelines by adopting a lifetime horizon (maximum age limited to 101 years) and a societal perspective, including all costs within the healthcare and individual costs like patients’ travel costs, informal car costs. Productivity costs were excluded due to the high age of patients. Disease progression was modelled through 24 health states, each defined by a discrete health state characterized by Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ TSS) quartiles. Furthermore, the incidence of hospitalizations for heart failure (HHF) and urgent heart failure visits (UHFV) was modelled. The health states and incidence of events were associated with costs and utility decrements.

Model input

In the DAPA-HF trial, dapagliflozin was found to be associated with statistically significant reductions in the primary composite outcome of cardiovascular (CV) death, hospitalization for HF (HFH) or urgent HF visit (UHFV) as a whole (hazard ratio: 0.74, 95% confidence interval: 0.65–0.85), and for each of the individual component endpoints (CV death: 0.82 [0.69–0.98], HFH: 0.70 [0.59–0.83], and UHFV: 0.43 [0.20–0.90]). Dapagliflozin was also associated in a nominal statistically significantly reduction in the incidence of all-cause mortality (ACM) (0.83, 0.71–0.97) [4].

Patient characteristics at initiation were based on the CHECK-HF study [5] (Mean age: 71 years, 34% females, 25% diabetes), which was considered representative for the Dutch HF population. Additional characteristics were sourced from the patient population in the DAPA-HF Trial. Transition rates, risks for events, mortality (all-cause mortality and cardiovascular specific mortality) and utilities were sourced from the DAPA-HF trial data. Additional input parameters for cost and utility decrements came from the Dutch costing manual, literature, and clinical expert opinion. Costs were discounted by 4.0%, effects by 1.5%. Beside the base-case analysis, one-way sensitivity analyses (OWSA), probabilistic sensitivity analysis (PSA) and scenarios analyses were performed. A burden of disease analysis using the IMTA IDBC tool showed that the relevant cost-effectiveness threshold for the patient population was €50,000/QALY in the Netherlands.

Results

The base case analysis resulted in a 0.55 gain in QALYs for dapagliflozin + SoC compared to SoC alone (Table 1). Cost for dapagliflozin were €3,593 higher, mainly due to the higher acquisition costs of dapagliflozin, which were somewhat compensated by a reduction in hospitalization costs. The resulting ICER was €6,507 per QALY gained. One-way sensitivity analysis varying input parameters by 20% showed that results were most sensitive to the input values used for health state utilities, societal costs and intervention costs (Figure 2). At a threshold of €50,000 per QALY, the cost-effectiveness acceptability curve showed that the probability that dapagliflozin was cost-effective was 100% (Figure 3).

Table 1: Lifetime cost-effectiveness dapagliflozin + SoC vs SoC alone (societal perspective discounted base-case analysis)

<table>
<thead>
<tr>
<th>Cost-effectiveness</th>
<th>Dapagliflozin + SoC</th>
<th>SoC</th>
<th>Incremental</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cost</td>
<td>€31,759</td>
<td>€28,167</td>
<td>€3,593</td>
</tr>
<tr>
<td>Medication costs</td>
<td>€4,222</td>
<td>€1,299</td>
<td>€2,923</td>
</tr>
<tr>
<td>HF treatment costs</td>
<td>€7,032</td>
<td>€7,107</td>
<td>€75</td>
</tr>
<tr>
<td>Adverse event costs</td>
<td>€674</td>
<td>€630</td>
<td>€45</td>
</tr>
<tr>
<td>Societal costs</td>
<td>€19,831</td>
<td>€19,131</td>
<td>€700</td>
</tr>
<tr>
<td>Total QALYs</td>
<td>5.197</td>
<td>4.645</td>
<td>0.552</td>
</tr>
<tr>
<td>Total life years</td>
<td>6.827</td>
<td>6.156</td>
<td>0.671</td>
</tr>
<tr>
<td>Incremental cost/QALY</td>
<td>€6,507</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incremental cost/LYG</td>
<td>-</td>
<td>€5,356</td>
<td></td>
</tr>
</tbody>
</table>

Erasmus University Rotterdam
Make it happen.

Main findings

- Base case results show that dapagliflozin in addition to standard of care results in an ICER of €6,507 per QALY gained.
- The likelihood of dapagliflozin being cost-effective at €50,000/QALY, the threshold relevant for the patient population, is 100%.
- The ICER is driven by gains in life-years and QALYs as a result of CV and All-Cause mortality benefits with Dapagliflozin in HFREF patients.
- Dapagliflozin is a cost-effective treatment option for chronic, symptomatic heart failure with reduced ejection fraction in the Netherlands.

Results (continued)

The most important scenario analyses are shown in Figure 4. When unrelated healthcare costs were included the ICER was €19,139. All scenario analyses resulted in ICERs below the €50,000/QALY threshold.

Figure 2: One-way sensitivity analyses for ICER

Figure 3: Acceptability curve dapagliflozin + SoC vs SoC alone

Figure 4: Scenario analysis: ICER dapagliflozin + SoC vs SoC alone

References


Table of content:

1. Objective
2. Methods
3. Results
4. Table 1: Lifetime cost-effectiveness dapagliflozin + SoC vs SoC alone (societal perspective discounted base-case analysis)
5. Main findings
6. Results (continued)
7. References